Maryland HB 666: Public Health - Expensive Drugs - Manufacturer Reporting and Drug Price Transparency Advisory Committee

Status: Hearing 2/23 at 1:00 p.m. (as of 2017-02-08)

State: Maryland · Session: 2017 · Bill: HB 666

Subjects: Public Health, Attorney General, Auditors and Audits, Committees and Commissions, Consumer Protection, Courts, Disclosure, Drugs, Electronic Communication, Electronic Government, Fees, General Assembly, Governor, Health and Mental Hygiene, Department of, Identification, Inspections, Penalties and Sentences, Pharmacists and Pharmacies, Public Information, Reports, Retail Sales, Rules and Regulations

Sponsors: Bromwell, A. Miller, A. Washington, Anderson, Atterbeary, B. Barnes, Barkley, Barve, Beidle, Branch, Brooks, C. Howard, C. Wilson, Carr, Chang, Clippinger, Conaway, Cullison, D. Barnes, Davis, Dumais, Ebersole, Fennell, Fraser-Hidalgo, Frick

View Maryland HB 666 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.